Welcome to our dedicated page for Tharimmune SEC filings (Ticker: THAR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tharimmune, Inc. (NASDAQ: THAR) SEC filings page on Stock Titan aggregates the company’s official disclosures filed with the U.S. Securities and Exchange Commission, including its Current Reports on Form 8-K, proxy materials, and other registration documents. These filings provide primary-source detail on Tharimmune’s clinical-stage biotechnology programs and its Canton Coin-focused digital asset treasury strategy.
Recent Form 8-K filings describe material definitive agreements such as securities purchase agreements for private placements involving common stock and pre-funded warrants, as well as an at-the-market sales agreement for common stock. They also outline the structure and intended use of proceeds from offerings designed to support both Tharimmune’s historical biotech operations and the establishment of a Canton Coin treasury and related Canton Network participation.
Other 8-Ks and proxy materials detail corporate governance and compensation matters, including amendments to the certificate of incorporation to increase authorized common stock, changes to the omnibus equity incentive plan, and the appointment of key executives such as the Chief Executive Officer, President, and Chief Financial Officer. These documents specify employment agreement terms, severance provisions, and equity award structures for senior leadership associated with the company’s biotechnology and digital asset initiatives.
Investors can also use this page to access risk factor discussions related to Tharimmune’s Canton Coin strategy, as described in its filings, including risks tied to digital asset volatility, regulatory uncertainty, and liquidity considerations. Proxy statements provide additional context on share authorization proposals and future offering authorizations under Nasdaq rules.
Stock Titan enhances these filings with AI-powered summaries that highlight key terms, capital structure changes, and leadership updates, helping readers quickly interpret complex legal and financial language. From here, you can review Tharimmune’s 8-Ks, registration statements, and proxy materials, and use the platform’s tools to track insider-related disclosures and ongoing financing arrangements as they appear in the EDGAR feed.
Tharimmune, Inc. (Nasdaq: THAR) filed a Form 8-K disclosing that Board member Kelly Anderson resigned, effective June 22, 2025, citing personal reasons. The filing, signed by CEO Sireesh Appajosyula on June 24, 2025, contains no indication of disagreement with management or issues related to the company’s operations, policies, or practices. No replacement director or related compensatory arrangements were announced. Aside from this governance change, the 8-K includes no financial data, strategic updates, or other material transactions.
Gravitas Capital LP, a significant insider at Tharimmune (THAR), has reported a substantial purchase of company shares. On June 20, 2025, the entity acquired 337,838 shares of Common Stock at a price of $1.48 per share, representing a total investment of approximately $500,000.
Following this transaction, Gravitas Capital LP now owns 732,424 shares directly. The reporting person holds multiple positions within the company, serving as:
- Executive Chairman
- Director
- 10% Owner
This insider purchase by a high-ranking executive and major shareholder could signal confidence in the company's future prospects. The transaction was reported within the required filing deadline, with the Form 4 being signed by Vincent LoPriore on June 23, 2025.
Form 4 filing reveals that Sanam Parikh, Director of Tharimmune (THAR), executed a direct purchase of company shares on June 20, 2025. The insider transaction details:
- Acquired 1,000 shares of Common Stock at $1.45 per share
- Total transaction value: $1,450
- Following the purchase, Parikh now holds 1,770 shares directly
This insider buying activity by a board member could signal confidence in the company's future prospects. The transaction was reported within the required filing window, with the Form 4 being signed on June 23, 2025. No derivative securities were involved in this transaction.
Insider Trading Alert: Sireesh Appajosyula, Chief Executive Officer and Director of Tharimmune (THAR), has increased their position through two separate purchase transactions on June 20, 2025:
- First purchase: 60,806 shares at $1.48 per share
- Second purchase: 690 shares at $1.42 per share
Following these transactions, Appajosyula directly owns 64,868 shares of Tharimmune common stock. The insider's decision to purchase shares on the open market could signal confidence in the company's future prospects. These purchases were reported via Form 4 within the required timeline, demonstrating compliance with SEC disclosure requirements.
Schedule 13D filing overview: Gravitas Capital LP and its managing member, Vincent S. LoPriore, disclosed beneficial ownership of 394,586 shares of Tharimmune, Inc. (ticker THAR), equal to 14.83 % of the outstanding common stock.
Acquisition chronology: (1) 104,586 shares purchased on 12-05-2024 at $2.1010 per share; (2) 290,000 pre-funded warrants exercised on 04-30-2025 at $0.001 per share. Aggregate cash deployed was $829,025.19, derived from Gravitas’s working capital.
Reporting structure: Gravitas Capital LP is a Delaware limited partnership whose general partner is Gravitas Capital Partners LLC. Mr. LoPriore is the managing member of that entity and is also Executive Chairman of Tharimmune, giving him indirect shared voting and dispositive power over the full position.
Intent & flexibility: The stake was acquired for investment purposes in the ordinary course of business. The filers state they currently have no concrete plans to effect corporate actions, but may continue to buy or sell shares and could engage management, other shareholders, or explore strategic alternatives as market and corporate developments evolve.
Other disclosures: No criminal or civil securities-law judgments in the past five years. No contracts or arrangements affecting the securities were identified, other than Mr. LoPriore’s position at President Street Global, LLC, a broker-dealer that has acted as placement agent for the issuer.
Tharimmune, Inc. (THAR) filed an 8-K announcing a private placement financing agreement signed on 13 June 2025. The company will issue 1,551,351 common shares and several warrant classes to a group of accredited investors.
- Pre-Funded Warrants: 137,838 shares, $0.001 exercise price, exercisable immediately until fully exercised.
- Series A Warrants: 1,689,189 shares, $1.29 exercise price, exercisable six months after issuance; 5.5-year term.
- Series B Warrants: 844,572 shares, $3.00 exercise price, exercisable six months after issuance; 5.5-year term.
The warrants include a 4.99% (optionally 9.99%) beneficial-ownership cap to limit post-exercise share concentration. Closing is expected on 20 June 2025, subject to customary conditions. Gross proceeds are estimated at approximately $2.5 million before placement-agent fees and offering expenses. Net proceeds are earmarked for clinical development programs and general working capital.
President Street Global acted as the exclusive placement agent. The securities purchase agreement and warrant forms are attached as Exhibits 10.1, 4.1, 4.2 and 4.3.
FAQ
What is the current stock price of Tharimmune (THAR)?
What is the market cap of Tharimmune (THAR)?
